VanEck Australia’s ETF doubles down on its CSL short position
VanEck’s long-short exchange-traded fund made the bold call to short CSL one month before the blood plasma giant’s earnings result erased more than $20 billion in market value.
The Australian long-short complex ETF first shorted – which makes money when a stock declines – CSL in early July and closed it out on August 20 after investors sent the shares plunging 17 per cent, spooked by the company’s plans to slash 3000 jobs and spin off its vaccine business.
Loading…
